CoChat
Sign Up
Cited by 23Attention Deficit Hyperactivity DisorderPharmacogenetics and Drug MetabolismNeurotransmitter Receptor Influence on Behavior

Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research

Open access
Elsayed, Nada A., Yamamoto, Kaila M., Froehlich, Tanya E.·2020·CNS Drugs
DOI 10.1007/s40263-020-00702-yPMC PMC8083895
Open this paper in CoChat — free account

Abstract

Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-consuming process due to the high inter-individual variability in treatment efficacy. As a result, there is growing interest in identifying predictors of ADHD medication response in children through the burgeoning field of pharmacogenomics. This article reviews childhood ADHD pharmacogenomics efficacy studies published during the last decade (2009-2019), which have largely focused on pharmacodynamic candidate gene investigations of methylphenidate and atomoxetine response, with a smaller number investigating pharmacokinetic candidate genes and genome-wide approaches. Findings from studies which have advanced the field of ADHD pharmacogenomics through investigation of meta-analytic approaches and gene-gene interactions are also overviewed. Despite recent progress, no one genetic variant or currently available pharmacogenomics test has demonstrated clinical utility in pinpointing the optimal ADHD medication for a given individual patient, highlighting the need for further investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40263-020-00702-y

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 130

  1. [6]Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. Journal of Developmental and Behavioral Pediatrics. 2007 8; 28(4): 274– 86. 17700079
  2. [8]Chang Z, Lichtenstein P, D’Onofrio BM, Sjolander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014 3; 71(3): 319– 25. 24477798 PMC3949159
  3. [10]Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015 8; 2(8): 702– 9. 26249301
  4. [12]Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, Medication for attention deficit-hyperactivity disorder and criminality. The New England journal of medicine. 2012 11 22; 367(21): 2006– 14. 23171097 PMC3664186
  5. [13]Lowe N, Barry E, Gill M, Hawi Z. An Overview of the Pharmacogenetics and Molecular Genetics of ADHD. Current Pharmacogenomics. 2006; 4: 231– 43.
  6. [14]Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child and adolescent psychiatric clinics of North America. 2008 4; 17(2): 475– 90, xi-xii. 18295157 PMC2413066
  7. [15]Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011 3; 89(3): 464– 7. 21270786 PMC3098762
  8. [17]Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O’Neill C, Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet. 2014 3; 166C(1): 76– 84. 24616408 PMC4066997
  9. [18]Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS drugs. 2010 2 1; 24(2): 99– 117. 20088618 PMC2874888
  10. [19]Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, Ensembl 2018. Nucleic Acids Res. 2018 1 4; 46(D1): D754– D61. 29155950 PMC5753206
  11. [20]Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural brain research. 1998 7; 94(1): 127– 52. 9708845
  12. [22]Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 8; 310(2): 469– 76. 15082749
  13. [23]Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009 12; 57(7–8): 731– 3. 19733552
  14. [24]Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. American journal of human genetics. 2008 6; 82(6): 1241– 8. 18485328 PMC2427248
  15. [25]Stage C, Jurgens G, Guski LS, Thomsen R, Bjerre D, Ferrero-Miliani L, The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. Br J Clin Pharmacol. 2017 7; 83(7): 1506– 14. 28087982 PMC5465325
  16. [26]Kaddurah-Daouk R, Hankemeier T, Scholl EH, Baillie R, Harms A, Stage C, Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. CPT Pharmacometrics Syst Pharmacol. 2018 8; 7(8): 525– 33. 30169917 PMC6118295
  17. [27]Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. J Child Adolesc Psychopharmacol. 2013 12; 23(10): 655– 64. 24350812
  18. [28]Nestler EJ, Hyman SE, Malenka RC. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. New York: The McGraw-Hill Companies, Inc.; 2001.
  19. [31]Hegvik TA, Jacobsen KK, Fredriksen M, Zayats T, Haavik J. A candidate gene investigation of methylphenidate response in adult attention-deficit/hyperactivity disorder patients: results from a naturalistic study. J Neural Transm (Vienna). 2016 8; 123(8): 859– 65. 27091191 PMC4969350
  20. [32]Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet. 1997 2; 51(2): 129– 30. 9112004
  21. [33]Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 11; 50(11): 1129– 39 e2. 22024001 PMC3225067
  22. [34]Kim BN, Cummins TD, Kim JW, Bellgrove MA, Hong SB, Song SH, Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val(6)(6)Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children. Int J Neuropsychopharmacol. 2011 11; 14(10): 1399– 410. 21733227
  23. [35]Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ. Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction? J Child Adolesc Psychopharmacol. 2012 10; 22(5): 343– 52. 23083021
  24. [36]Park S, Kim JW, Kim BN, Hong SB, Shin MS, Yoo HJ, No significant association between the alpha-2A-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attention-deficit hyperactivity disorder. Pharmacopsychiatry. 2013 7; 46(5): 169– 74. 23824524
  25. [38]Cheon KA, Cho DY, Koo MS, Song DH, Namkoong K. Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2009 4 1; 65(7): 564– 70. 19150055
  26. [39]Huang HC, Wu LS, Yu SC, Wu BJ, Lua AC, Lee SM, The Alpha-2A Adrenergic Receptor Gene −1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder. Psychiatry Investig. 2018 3; 15(3): 306– 12. PMC5900374 29486545
  27. [40]Unal D, Unal MF, Alikasifoglu M, Cetinkaya A. Genetic Variations in Attention Deficit Hyperactivity Disorder Subtypes and Treatment Resistant Cases. Psychiatry Investig. 2016 7; 13(4): 427– 33. PMC4965653 27482244
  28. [41]Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2018 9; 23(9): 1929– 36. 29230023 PMC7039663
  29. [42]Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2013 6; 33(3): 356– 62. 23609393
  30. [43]Trzaska KA, King CC, Li KY, Kuzhikandathil EV, Nowycky MC, Ye JH, Brain-derived neurotrophic factor facilitates maturation of mesenchymal stem cell-derived dopamine progenitors to functional neurons. J Neurochem. 2009 8; 110(3): 1058– 69. 19493166
  31. [45]Ho BC, Milev P, O’Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry. 2006 7; 63(7): 731– 40. 16818862 PMC3065118
  32. [46]Flanagin BA, Cook EH Jr., de Wit H. An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet. 2006 9 5; 141B(6): 576– 83. 16823800 PMC2556402
  33. [47]Napolitano A, Cesura AM, Da Prada M. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J Neural Transm Suppl. 1995; 45: 35– 45. 8748607
  34. [49]McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009 12; 48(12): 1155– 64. 19858760 PMC2888980
  35. [50]Park S, Kim JW, Kim BN, Shin MS, Yoo HJ, Cho SC. Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea. J Psychopharmacol. 2014 7; 28(7): 671– 6. 24763183
  36. [51]Pagerols M, Richarte V, Sanchez-Mora C, Garcia-Martinez I, Corrales M, Corominas M, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder. Pharmacogenomics J. 2017 1; 17(1): 98– 104. 26810137
  37. [52]Yatsuga C, Toyohisa D, Fujisawa TX, Nishitani S, Shinohara K, Matsuura N, No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children. Brain Dev. 2014 8; 36(7): 620– 5. 24035255
  38. [53]Salatino-Oliveira A, Genro JP, Zeni C, Polanczyk GV, Chazan R, Guimaraes AP, Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011 8 1; 70(3): 216– 21. 21550019
  39. [54]Kaufman S, Friedman S. Dopamine-Beta-Hydroxylase. Pharmacol Rev. 1965 6; 17: 71– 100. 14294032
  40. [55]Ribases M, Ramos-Quiroga JA, Hervas A, Sanchez-Mora C, Bosch R, Bielsa A, Candidate system analysis in ADHD: evaluation of nine genes involved in dopaminergic neurotransmission identifies association with DRD1. World J Biol Psychiatry. 2012 4; 13(4): 281– 92. 22404661
  41. [56]Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014 12 12; 282: 13– 22. 24463000 PMC4108583
  42. [57]Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997 12; 7(6): 479– 84. 9429233
  43. [58]Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998 5; 3(3): 256– 60. 9672901
  44. [59]Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A. 2007 12 18; 104(51): 20552– 7. 18077373 PMC2154469
  45. [60]Wu J, Xiao H, Sun H, Zou L, Zhu LQ. Role of dopamine receptors in ADHD: a systematic meta-analysis. Mol Neurobiol. 2012 6; 45(3): 605– 20. 22610946
  46. [61]Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 7 11; 103(28): 10753– 8. 16809426 PMC1502303
  47. [62]Fageera W, Sengupta SM, Labbe A, Grizenko N, Joober R. DRD3 Gene and ADHD: A Pharmaco-Behavioural Genetic Study. Neuromolecular Med. 2018 12; 20(4): 515– 24. 30051166
  48. [63]Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011 3; 63(1): 182– 217. 21303898
  49. [64]Wong AH, Van Tol HH. The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003 10; 27(7): 1091– 9. 14642969
  50. [65]Pappa I, Mileva-Seitz VR, Bakermans-Kranenburg MJ, Tiemeier H, van IMH. The magnificent seven: A quantitative review of dopamine receptor d4 and its association with child behavior. Neurosci Biobehav Rev. 2015 10; 57: 175– 86. 26297813
  51. [66]Naumova D, Grizenko N, Sengupta SM, Joober R. DRD4 exon 3 genotype and ADHD: Randomised pharmacodynamic investigation of treatment response to methylphenidate. World J Biol Psychiatry. 2017 12 15: 1– 10. 29182037
  52. [67]Ji HS, Paik KC, Park WS, Lim MH. No Association between the Response to Methylphenidate and DRD4 Gene Polymorphism in Korean Attention Deficit Hyperactivity Disorder: A Case Control Study. Clin Psychopharmacol Neurosci. 2013 4; 11(1): 13– 7. 23678349 PMC3650292
  53. [68]D’Souza UM, Russ C, Tahir E, Mill J, McGuffin P, Asherson PJ, Functional effects of a tandem duplication polymorphism in the 5’flanking region of the DRD4 gene. Biol Psychiatry. 2004 11 1; 56(9): 691– 7. 15522254
  54. [69]Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002; 6 Suppl 1: S31– 43. 12685517
  55. [70]Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry. 1999 12; 38(12): 1474– 7. 10596245
  56. [71]Stein MA, Waldman I, Newcorn J, Bishop J, Kittles R, Cook EH Jr. Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014 6; 24(5): 238– 44. 24813374 PMC4064733
  57. [73]Soleimani R, Salehi Z, Soltanipour S, Hasandokht T, Jalali MM. SLC6A3 polymorphism and response to methylphenidate in children with ADHD: A systematic review and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2018 4; 177(3): 287– 300. 29171685
  58. [74]Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D’Souza UM. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am J Med Genet B Neuropsychiatr Genet. 2007 12 5; 144B(8): 1070– 8. 17579365
  59. [75]Arcos-Burgos M, Jain M, Acosta MT, Shively S, Stanescu H, Wallis D, A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication. Mol Psychiatry. 2010 11; 15(11): 1053– 66. 20157310
  60. [76]Song J, Kim SW, Hong HJ, Lee MG, Lee BW, Choi TK, Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. Clin Neuropharmacol. 2014 Sep-Oct; 37(5): 136– 41. 25229170
  61. [77]Bruxel EM, Salatino-Oliveira A, Akutagava-Martins GC, Tovo-Rodrigues L, Genro JP, Zeni CP, LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study. Genes Brain Behav. 2015 6; 14(5): 419– 27. 25989180
  62. [78]Labbe A, Liu A, Atherton J, Gizenko N, Fortier ME, Sengupta SM, Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD. Am J Med Genet B Neuropsychiatr Genet. 2012 10; 159B(7): 776– 85. 22851411
  63. [79]Choudhry Z, Sengupta SM, Grizenko N, Fortier ME, Thakur GA, Bellingham J, LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy. J Child Psychol Psychiatry. 2012 8; 53(8): 892– 902. 22486528
  64. [81]Fisher NM, Seto M, Lindsley CW, Niswender CM. Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders. Front Mol Neurosci. 2018; 11: 387. 30405350 PMC6206046
  65. [82]Park S, Kim BN, Cho SC, Kim JW, Kim JI, Shin MS, The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014 5; 24(4): 223– 7. 24815731
  66. [83]Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 12 5; 147B(8): 1412– 8. 18821564
  67. [84]Pagerols M, Richarte V, Sanchez-Mora C, Rovira P, Soler Artigas M, Garcia-Martinez I, Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. Sci Rep. 2018 1 30; 8(1): 1881. 29382897 PMC5789875
  68. [86]Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci. 2000 5; 3(5): 465– 71. 10769386
  69. [87]Carboni E, Silvagni A, Vacca C, Di Chiara G. Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem. 2006 1; 96(2): 473– 81. 16336224
  70. [90]Jonsson EG, Nothen MM, Gustavsson JP, Neidt H, Bunzel R, Propping P, Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res. 1998 6 2; 79(1): 1– 9. 9676821
  71. [91]Kim BN, Kim JW, Hong SB, Cho SC, Shin MS, Yoo HJ. Possible association of norepinephrine transporter −3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behav Brain Funct. 2010 10 7; 6: 57. 20929549 PMC2959002
  72. [92]Lee SH, Kim SW, Lee MG, Yook KH, Greenhill LL, Fradin KN, Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD. Psychiatry Res. 2011 4 30; 186(2–3): 338– 44. 20863575
  73. [93]Angyal N, Horvath EZ, Tarnok Z, Richman MJ, Bognar E, Lakatos K, Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients. Prog Neuropsychopharmacol Biol Psychiatry. 2018 6 8; 84(Pt A): 122– 8. 29374517
  74. [94]Song J, Song DH, Jhung K, Cheon KA. Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. Int Clin Psychopharmacol. 2011 3; 26(2): 107– 13. 21127421
  75. [95]Park MH, Kim JW, Yang YH, Hong SB, Park S, Kang H, Regional brain perfusion before and after treatment with methylphenidate may be associated with the G1287A polymorphism of the norepinephrine transporter gene in children with attention-deficit/hyperactivity disorder. Neurosci Lett. 2012 4 18; 514(2): 159– 63. 22405810
  76. [97]Thakur GA, Sengupta SM, Grizenko N, Choudhry Z, Joober R. Comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD: relation to maternal smoking during pregnancy. PloS one. 2012; 7(11): e49616. 23185385 PMC3502190
  77. [98]Hu C, Chen W, Myers SJ, Yuan H, Traynelis SF. Human GRIN2B variants in neurodevelopmental disorders. J Pharmacol Sci. 2016 10; 132(2): 115– 21. 27818011 PMC5125235
  78. [99]Wanchoo SJ, Swann AC, Dafny N. Descending glutamatergic pathways of PFC are involved in acute and chronic action of methylphenidate. Brain Res. 2009 12 8; 1301: 68– 79. 19747456 PMC3271787
  79. [100]dbSNP Short Genetic Variations rs2284411 Reference SNP Report. [cited 2019 August 15 ]; Available from: https://www.ncbi.nlm.nih.gov/snp/rs2284411#publications
  80. [101]Kim JI, Kim JW, Park JE, Park S, Hong SB, Han DH, Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder. J Psychopharmacol. 2017 8; 31(8): 1070– 7. 27624150
  81. [102]Fishbein DH, Lozovsky D, Jaffe JH. Impulsivity, aggression, and neuroendocrine responses to serotonergic stimulation in substance abusers. Biol Psychiatry. 1989 4 15; 25(8): 1049– 66. 2720017
  82. [103]Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 11 29; 274(5292): 1527– 31. 8929413
  83. [104]Hanna GL, Himle JA, Curtis GC, Koram DQ, Veenstra-VanderWeele J, Leventhal BL, Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology. 1998 2; 18(2): 102– 11. 9430134
  84. [105]Thakur GA, Grizenko N, Sengupta SM, Schmitz N, Joober R. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. BMC psychiatry. 2010; 10: 50. 20569447 PMC2905344
  85. [106]Park SY, Kim EJ, Cheon KA. Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2015 10; 25(8): 633– 40. 26402385 PMC4615776
  86. [107]Zeni CP, Guimaraes AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2007 4 5; 144(3): 391– 4. 17171656
  87. [108]Tharoor H, Lobos EA, Todd RD, Reiersen AM. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet. 2008 6 5; 147B(4): 527– 30. 17948872
  88. [109]Seeger G, Schloss P, Schmidt MH. Marker gene polymorphisms in hyperkinetic disorder--predictors of clinical response to treatment with methylphenidate? Neurosci Lett. 2001 11 2; 313(1–2): 45– 8. 11684336
  89. [110]Schiavo G, Stenbeck G, Rothman JE, Sollner TH. Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Proc Natl Acad Sci U S A. 1997 2 4; 94(3): 997– 1001. 9023371 PMC19628
  90. [112]Nagatsu T, Levitt M, Udenfriend S. Conversion of L-tyrosine to 3,4-dihydroxyphenylalanine by cell-free preparations of brain and sympathetically innervated tissues. Biochem Biophys Res Commun. 1964; 14: 543– 9. 5836553
  91. [113]Nagatsu T, Levitt M, Udenfriend S. Tyrosine Hydroxylase. The Initial Step in Norepinephrine Biosynthesis. J Biol Chem. 1964 9; 239: 2910– 7. 14216443
  92. [114]Wang L, Li B, Lu X, Zhao Q, Li Y, Ge D, A functional intronic variant in the tyrosine hydroxylase (TH) gene confers risk of essential hypertension in the Northern Chinese Han population. Clin Sci (Lond). 2008 9; 115(5): 151– 8. 18208403
  93. [115]Hohman TJ, Bush WS, Jiang L, Brown-Gentry KD, Torstenson ES, Dudek SM, Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging. 2016 2; 38: 141– 50. 26827652 PMC4735733
  94. [116]Lesch KP, Timmesfeld N, Renner TJ, Halperin R, Roser C, Nguyen TT, Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J Neural Transm (Vienna). 2008 11; 115(11): 1573– 85. 18839057
  95. [117]Lyon GJ, Jiang T, Van Wijk R, Wang W, Bodily PM, Xing J, Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications. Discov Med. 2011 7; 12(62): 41– 55. 21794208 PMC3544941
  96. [118]Lugowska A, Mierzewska H, Bekiesinska-Figatowska M, Szczepanik E, Goszczanska-Ciuchta A, Bednarska-Makaruk M. A homozygote for the c.459+1G>A mutation in the ARSA gene presents with cerebellar ataxia as the only first clinical sign of metachromatic leukodystrophy. J Neurol Sci. 2014 3 15; 338(1–2): 214– 7. 24411407
  97. [119]Steingard R, Taskiran S, Connor DF, Markowitz JS, Stein MA. New Formulations of Stimulants: An Update for Clinicians. J Child Adolesc Psychopharmacol. 2019 6; 29(5): 324– 39. 31038360 PMC7207053
  98. [120]Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 6 1; 53(11): 1605– 12. 9264312
  99. [121]Gehlert DR, Gackenheimer SL, Robertson DW. Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett. 1993 7 23; 157(2): 203– 6. 8233054
  100. [122]Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982 7; 222(1): 61– 5. 6123593
  101. [123]Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2): 89– 295. 19514967
  102. [124]Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002 3; 30(3): 319– 23. 11854152
  103. [125]Yu G, Li GF, Markowitz JS. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. J Child Adolesc Psychopharmacol. 2016 5; 26(4): 314– 26. 26859445 PMC4876529
  104. [126]Ramoz N, Boni C, Downing AM, Close SL, Peters SL, Prokop AM, A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009 8; 34(9): 2135– 42. 19387424
  105. [127]Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007 2; 46(2): 242– 51. 17242628
  106. [128]Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008 2; 18(2): 79– 86. 17698328
  107. [129]Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 7; 106(1): 94– 102. 30801677 PMC6612570
  108. [130]Fang Y, Ji N, Cao Q, Su Y, Chen M, Wang Y, Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2015 10; 25(8): 625– 32. 26447643 PMC4615817
  109. [131]Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology. 2007 2; 52(2): 405– 14. 17020775
  110. [132]Yang L, Qian Q, Liu L, Li H, Faraone SV, Wang Y. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm (Vienna). 2013 7; 120(7): 1127– 33. 23266789
  111. [133]Kim CH, Kim HS, Cubells JF, Kim KS. A previously undescribed intron and extensive 5’ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem. 1999 3 5; 274(10): 6507– 18. 10037744
  112. [134]Briars L, Todd T. A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder. J Pediatr Pharmacol Ther. 2016 May-Jun; 21(3): 192– 206. 27453697 PMC4956327
  113. [135]Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 9; 38(9): 1393– 6. 20570945 PMC2939473
  114. [136]Polanczyk G, Faraone SV, Bau CH, Victor MM, Becker K, Pelz R, The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am J Med Genet B Neuropsychiatr Genet. 2008 12 5; 147B(8): 1419– 24. 18802923 PMC2587514
  115. [137]Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome-wide association studies in diverse populations. Nat Rev Genet. 2010 5; 11(5): 356– 66. 20395969 PMC3079573
  116. [138]Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, Contini V, Kieling C, Hutz MH, ADHD pharmacogenetics across the life cycle: New findings and perspectives. Am J Med Genet B Neuropsychiatr Genet. 2014 6; 165(4): 263– 82. 24804845
  117. [139]Wehry AM, Ramsey L, Dulemba SE, Mossman SA, Strawn JR. Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Curr Probl Pediatr Adolesc Health Care. 2018 2; 48(2): 40– 9. 29325731 PMC5828875
  118. [142]Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin Neurosci. 2014 9; 16(3): 395– 404. 25364288 PMC4214180
  119. [144]Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT, Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry. 2013 4; 18(4): 398– 9. 22547115 PMC5319860
  120. [145]Yehuda R, Daskalakis NP, Desarnaud F, Makotkine I, Lehrner AL, Koch E, Epigenetic Biomarkers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Veterans with PTSD. Front Psychiatry. 2013; 4: 118. 24098286 PMC3784793
  121. [146]Tang H, Dalton CF, Srisawat U, Zhang ZJ, Reynolds GP. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. Int J Neuropsychopharmacol. 2014 4; 17(4): 645– 9. 24331356
  122. [147]Powell TR, Smith RG, Hackinger S, Schalkwyk LC, Uher R, McGuffin P, DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl Psychiatry. 2013 9 3; 3: e300. 24002086 PMC3784763
  123. [148]Domschke K, Tidow N, Schwarte K, Deckert J, Lesch KP, Arolt V, Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol. 2014 8; 17(8): 1167– 76. 24679990
  124. [149]Burghardt KJ, Goodrich JM, Dolinoy DC, Ellingrod VL. Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. Bipolar Disord. 2016 8; 18(5): 423– 32. 27542345 PMC5322870
  125. [150]Ovenden ES, McGregor NW, Emsley RA, Warnich L. DNA methylation and antipsychotic treatment mechanisms in schizophrenia: Progress and future directions. Prog Neuropsychopharmacol Biol Psychiatry. 2018 2 2; 81: 38– 49. 29017764
  126. [151]Sugawara H, Bundo M, Ishigooka J, Iwamoto K, Kato T. Epigenetic regulation of serotonin transporter in psychiatric disorders. J Genet Genomics. 2013 7 20; 40(7): 325– 9. 23876772
  127. [152]Abdolmaleky HM, Pajouhanfar S, Faghankhani M, Joghataei MT, Mostafavi A, Thiagalingam S. Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (dysbindin) promoter in saliva and post-mortem brain of patients with schizophrenia and Psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2015 12; 168(8): 687– 96. 26285059
  128. [153]Rukova B, Staneva R, Hadjidekova S, Stamenov G, Milanova V, Toncheva D. Whole genome methylation analyses of schizophrenia patients before and after treatment. Biotechnol Biotechnol Equip. 2014 5 4; 28(3): 518– 24. 26019538 PMC4434134
  129. [154]Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiology of disease. 2009 8; 35(2): 165– 76. 19303440
  130. [156]Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenetics and genomics. 2012 4; 22(4): 247– 53. 22322242 PMC3303952

Cited by

Sorted by citations

Authors
Elsayed, N. A., Yamamoto, K. M., & Froehlich, T. E.
Affiliations
Cincinnati Children's Hospital Medical Center (US)
Corresponding author
Froehlich, Tanya E.
ORCID
Froehlich, Tanya E.
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2020-03-04
Volume
34
Issue
4
Pages
389-414
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
DOI
10.1007/s40263-020-00702-y
PMC
PMC8083895
OpenAlex
W3010185637
Cited by
23
References
22
Citations by year
2026: 2 · 2025: 2 · 2023: 7 · 2022: 11 · 2021: 1
FWCI
0.79
Type
journal article
Language
en
Open access
Licence
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (R01MH105425)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
attention deficit hyperactivity disorder, pharmacogenomics, children with ADHD, stimulant medication, methylphenidate, atomoxetine, candidate genes, pharmacokinetic genes, gene-gene interaction, treatment response prediction, genome-wide association study, meta-analysis
MeSH terms
Animals, Attention Deficit Disorder with Hyperactivity, Child, Pharmaceutical Preparations, Humans, Pharmacogenetics, Genetic Variation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review